June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Sentara Creates Advanced Cardiac Imaging Team

Sentara's robust cardiovascular program continues to grow in expertise and technological improvements. One of the most recent additions is the Advanced Cardiac Imaging Team (ACIT).

Sentara

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Could Age Predict DVT in Cellulitis?

A 10-year study found that individuals aged 70 and above with lower limb cellulitis had significantly higher odds of developing deep vein thrombosis.

Conexiant

June 27, 2025

Playing With His Whole Heart

In pursuing his lifelong passion for athletics, Collin Liberty has never let anything stand in his way. A soccer enthusiast from childhood, Liberty was determined to play the sport in college and then launch a professional soccer career.

Cedars-Sinai Pulse

June 27, 2025

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant

June 27, 2025

CGM Boosts Wound Healing, Lowers A1c: Study

Short-term CGM use improved A1c, wound healing, and reduced ED visits in diabetic foot patients, per data from ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

Ecnoglutide Shows Strong Weight Loss in Trial

A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

New Guidance Targets Risk-Based Diabetes Care

A new review outlines updated strategies for diagnosing and managing type 2 diabetes, recommending earlier use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with cardiovascular or kidney conditions.

Conexiant